Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
24 May, 2018 21:31 IST
Zydus receives approval from USFDA for Mesalamine suppositories
Source: IRIS | 11 Aug, 2017, 05.12PM
Comments  |  Post Comment

Zydus Cadila has received the tentative approval from the USFDA to market Mesalamine Suppositories for rectal use, 1000 mg.

Mesalamine is used to treat an inflammatory bowel disease, such as ulcerative colitis. It will be produced at the group's Topical plant at Ahmedabad.

The group now has more than 140 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.

Shares of the company gained Rs 17.55, or 3.77%, to settle at Rs 482.95. The total volume of shares traded was 401,757 at the BSE (Friday).





Cadila Healthcare Limited   (Q,N,C,F)*

Comments Post comment 
 Post Comment
Name Email
Comment
Security Code type    into this box
Related Articles
MCX Strengthens its Precious Metals Suite with the Launch of Silver Options - 24-May-2018 17:54
Granules India quarterly earnings plummet 55% - 24-May-2018 17:04
GAIL (India) quarterly profit zooms 3.92 times - 24-May-2018 16:58
Jet Airways turns to loss in Jan-Mar quarter - 24-May-2018 16:45
Gayatri Projects bags order worth Rs 4.25 bn - 24-May-2018 16:37
Tata Steel's Bhushan buy to raise net leverage, offset gains from Europe JV: Fitch - 24-May-2018 16:25
Tata Steel's Bhushan buy to raise net leverage, offset gains from Europe JV: Fitch - 24-May-2018 16:25
L&T Construction wins order worth Rs 21.12 bn - 24-May-2018 16:22
Newspaper Publications Of Intimation Of Board Meeting - 24-May-2018 12:16
NITI Aayog and ABB India partner to make India AI-Ready - 23-May-2018 15:39
TCS update on multi-year agreement with Transamerica - 23-May-2018 15:21
more...
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer